Ventyx Biosciences (VTYX)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	28.24 mm	28.24 mm	28.24 mm	28.24 mm	28.24 mm	28.24 mm
Cash burn (monthly)	11.50 mm	2.03 mm	10.81 mm	12.37 mm	7.75 mm	10.91 mm
Cash used (since last report)	43.44 mm	7.65 mm	40.82 mm	46.73 mm	29.27 mm	41.19 mm
Cash remaining	-15.21 mm	20.58 mm	-12.58 mm	-18.49 mm	-1.04 mm	-12.96 mm
Runway (months of cash)	-1.3	10.2	-1.2	-1.5	-0.1	-1.2

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q4 2024

VTYX institutional ownership history Ownership history

94.2% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	126	122	+3.3%
Opened positions	27	21	+28.6%
Closed positions	23	19	+21.1%
Increased positions	46	44	+4.5%
Reduced positions	28	30	-6.7%

13F shares	Current	Prev Q	Change
Total value	117.96 bn	113.38 bn	+4.0%
Total shares	67.04 mm	71.30 mm	-6.0%
Total puts	186.70 k	83.00 k	+124.9%
Total calls	114.70 k	35.30 k	+224.9%
Total put/call ratio	1.6	2.4	-30.8%

Largest owners	Shares	Value	Change
NSV Investments I	6.26 mm	$15.59 mm	0.0%
BlackRock	4.50 mm	$9.86 bn	-8.3%
Citadel Advisors	4.48 mm	$9.81 bn	+0.6%
BAC Bank of America	4.27 mm	$9.36 bn	+376.4%
Sio Capital Management	4.05 mm	$8.86 bn	+105.2%
UBS UBS	3.78 mm	$8.28 bn	+215.9%
Vanguard	3.51 mm	$7.68 bn	+1.2%
Tang Capital Partners	3.10 mm	$6.11 mm	0.0%
Tang Capital Management	3.10 mm	$6.79 bn	0.0%
venBio Global Strategic Fund III	2.72 mm	$112.81 mm	0.0%

Largest transactions	Shares	Bought/sold	Change
Deerfield Management	534.74 k	-6.18 mm	-92.0%
Flynn James E	534.74 k	-6.18 mm	-92.0%
BAC Bank of America	4.27 mm	+3.38 mm	+376.4%
Farallon Capital Management	0.00	-3.17 mm	EXIT
UBS UBS	3.78 mm	+2.59 mm	+215.9%
Octagon Capital Advisors	0.00	-2.39 mm	EXIT
MS Morgan Stanley	2.51 mm	+2.18 mm	+654.7%
Sio Capital Management	4.05 mm	+2.07 mm	+105.2%
Redmile	124.18 k	-1.98 mm	-94.1%
Point72 Asset Management	1.78 mm	+1.74 mm	+3717.1%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

VTYX insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
2 Apr 25	John Nuss	Common Stock	Sell	Dispose S	No	No	1.07	1,887	2.02 k	467,226
28 Mar 25	Somu Subramaniam	Common Stock	Other	Dispose J	Yes	No	0	1,335,450	0.00	4,032,213
28 Mar 25	John Nuss	Common Stock	Option exercise	Acquire M	No	No	0	4,531	0.00	469,113
28 Mar 25	John Nuss	RSU Common Stock	Option exercise	Dispose M	No	No	0	4,531	0.00	9,063
28 Mar 25	Raju Mohan	Common Stock	Option exercise	Acquire M	No	No	0	11,844	0.00	2,303,540
28 Mar 25	Raju Mohan	RSU Common Stock	Option exercise	Dispose M	No	No	0	11,844	0.00	23,688
10 Mar 25	Somu Subramaniam	Common Stock	Other	Dispose J	Yes	No	0	1,735,306	0.00	5,367,663

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Ventyx Biosciences Q4 EPS $(0.41) Beats $(0.54) Estimate

27 Feb 25

Ventyx Biosciences (NASDAQ:VTYX) reported quarterly losses of $(0.41) per share which beat the analyst consensus estimate of $(0.54) by 24.07 percent. This is a 48.1 percent increase over losses of $(0.79) per share from

Ventyx Biosciences Announces Presentation Of Data From The Phase 2 Trial Of Allosteric TYK2 Inhibitor VTX958 In Crohn's Disease At ECCO 2025

18 Feb 25

Poster highlights robust, dose-dependent endoscopic response with VTX958 and reductions in key inflammatory markersFull analysis of Phase 2 results, including data from the 52-week treat-through LTE phase, is expected to